Literature DB >> 21546497

An overview of the progress on double umbilical cord blood transplantation.

Anastasia Sideri1, Nikolaos Neokleous, Philippe Brunet De La Grange, Bernadette Guerton, Marie-Caroline Le Bousse Kerdilles, Georges Uzan, Corina Peste-Tsilimidos, Eliane Gluckman.   

Abstract

Umbilical cord blood transplantation has been increasingly used over the past years for both malignant and non-malignant hematologic and other diseases as an alternative to mismatched-related or matched-unrelated bone marrow or peripheral blood hematopoietic stem cell transplantation. A disadvantage of cord blood is its low cell content which limits cord blood transplantation to generally low weight recipients, such as children. Various alternatives have been used to overcome this limitation, including co-infusion of two partially HLA-matched cord blood units. According to Eurocord Registry data, this strategy has been applied in approximately 993 adult patients with hematologic diseases since the first double umbilical cord blood transplantation in 1999. In fact, since 2005, the number of adult patients receiving double umbilical cord blood transplantation has surpassed the number of adults transplanted with single cord blood units. The engraftment rate is comparable for both single and double umbilical cord blood transplantation, although the latter is accompanied by a higher incidence of grade II acute graft-versus-host disease and lower leukemia relapse for patients in first complete remission. In the majority of patients undergoing double umbilical cord blood transplantation, transient chimerism, due to the presence of cells from both donor units early post transplant, is replaced by sustained dominance of one unit from which long-term hematopoiesis is derived. Although the biology and the factors that determine unit dominance have not been clarified, the implication of immune-mediated mechanisms has been reported. Preliminary data have demonstrated the safety of double umbilical cord blood transplantation. Ongoing clinical trials and prolonged follow up of the patients will clarify the immunology and determine the efficacy of this approach. We present here a brief overview of the clinical experience on double umbilical cord blood transplantation and its underlying biology.

Entities:  

Mesh:

Year:  2011        PMID: 21546497      PMCID: PMC3148916          DOI: 10.3324/haematol.2010.038836

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  67 in total

1.  Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches.

Authors:  S K Nilsson; H M Johnston; J A Coverdale
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

2.  UCB and atmospheric noise.

Authors:  Michael R Verneris; John E Wagner
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

3.  Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation.

Authors:  R L Haspel; G Kao; B Y Yeap; C Cutler; R J Soiffer; E P Alyea; V T Ho; J Koreth; B R Dey; S L McAfee; E C Attar; T Spitzer; J H Antin; K K Ballen
Journal:  Bone Marrow Transplant       Date:  2007-11-26       Impact factor: 5.483

Review 4.  State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants.

Authors:  Naynesh Kamani; Stephen Spellman; Carolyn Katovich Hurley; Juliet N Barker; Franklin O Smith; Machteld Oudshoorn; Robert Bray; Anajane Smith; Thomas M Williams; Brent Logan; Mary Eapen; Claudio Anasetti; Michelle Setterholm; Dennis L Confer
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

Review 5.  Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications.

Authors:  Colleen Delaney; Jonathan A Gutman; Frederick R Appelbaum
Journal:  Br J Haematol       Date:  2009-10       Impact factor: 6.998

6.  Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution.

Authors:  Colleen Delaney; Shelly Heimfeld; Carolyn Brashem-Stein; Howard Voorhies; Ronald L Manger; Irwin D Bernstein
Journal:  Nat Med       Date:  2010-01-17       Impact factor: 53.440

7.  HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.

Authors:  Katarina Le Blanc; Charlotte Tammik; Kerstin Rosendahl; Eva Zetterberg; Olle Ringdén
Journal:  Exp Hematol       Date:  2003-10       Impact factor: 3.084

8.  Stable mixed donor-donor chimerism after double cord blood transplantation.

Authors:  Sofia Berglund; Mantas Okas; Jens Gertow; Michael Uhlin; Jonas Mattsson
Journal:  Int J Hematol       Date:  2009-08-22       Impact factor: 2.490

9.  Pre-engraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versus-host disease.

Authors:  Kevin J Patel; Robert D Rice; Rebecca Hawke; Michelle Abboud; Glenn Heller; Andromachi Scaradavou; James W Young; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-24       Impact factor: 5.742

Review 10.  Ten years of cord blood transplantation: from bench to bedside.

Authors:  Eliane Gluckman
Journal:  Br J Haematol       Date:  2009-10       Impact factor: 6.998

View more
  28 in total

1.  Knowledge about umbilical cord blood banking among Greek citizens.

Authors:  Louiza Z Karagiorgou; Maria-Nikoletta P Pantazopoulou; Nikolaos C Mainas; Apostolos I Beloukas; Anastasios G Kriebardis
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

Review 2.  Cord blood research, banking, and transplantation: achievements, challenges, and perspectives.

Authors:  Hector Mayani; John E Wagner; Hal E Broxmeyer
Journal:  Bone Marrow Transplant       Date:  2019-05-14       Impact factor: 5.483

Review 3.  Wharton's Jelly Mesenchymal Stromal Cells as a Feeder Layer for the Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells: a Review.

Authors:  Melania Lo Iacono; Rita Anzalone; Giampiero La Rocca; Elena Baiamonte; Aurelio Maggio; Santina Acuto
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

Review 4.  Advances in haplo-identical stem cell transplantation in adults with high-risk hematological malignancies.

Authors:  Michael J Ricci; Jeffrey A Medin; Ronan S Foley
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

Review 5.  Cell based therapies for ischemic stroke: from basic science to bedside.

Authors:  Xinfeng Liu; Ruidong Ye; Tao Yan; Shan Ping Yu; Ling Wei; Gelin Xu; Xinying Fan; Yongjun Jiang; R Anne Stetler; George Liu; Jieli Chen
Journal:  Prog Neurobiol       Date:  2013-12-12       Impact factor: 11.685

6.  Stem cell factor is essential for preserving NOD/SCID reconstitution capacity of ex vivo expanded cord blood CD34(+) cells.

Authors:  Zheng Du; Ziyan Wang; Weiwei Zhang; Haibo Cai; Wen-Song Tan
Journal:  Cell Prolif       Date:  2015-04-21       Impact factor: 6.831

Review 7.  Fish to Learn: Insights into Blood Development and Blood Disorders from Zebrafish Hematopoiesis.

Authors:  Serine Avagyan; Leonard I Zon
Journal:  Hum Gene Ther       Date:  2016-04       Impact factor: 5.695

8.  Importance of day 21 BM chimerism in sustained neutrophil engraftment following double-unit cord blood transplantation.

Authors:  S Avery; M H Voss; A M Gonzales; M Lubin; H Castro-Malaspina; S Giralt; N A Kernan; A Scaradavou; C V Hedvat; C E Stevens; J N Barker
Journal:  Bone Marrow Transplant       Date:  2011-12-05       Impact factor: 5.483

Review 9.  Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies.

Authors:  Daniel Kl Cheuk
Journal:  World J Transplant       Date:  2013-12-24

Review 10.  Effect of HLA mismatch on acute graft-versus-host disease.

Authors:  Junya Kanda
Journal:  Int J Hematol       Date:  2013-07-28       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.